日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial

作者更正：一线改良FOLFOX方案联合/不联合纳武利尤单抗和伊匹木单抗或FLOT方案联合纳武利尤单抗治疗晚期胃食管腺癌：一项II期多队列IKF-AIO-MOONLIGHT试验

期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-026-72255-5
Lorenzen, Sylvie; Goetze, Thorsten Oliver; Thuss-Patience, Peter C; Riera-Knorrenschild, Jorge; Goekkurt, Eray; Dechow, Tobias Nicolaas; Ettrich, Thomas Jens; Hofheinz, Ralf Dieter; Luley, Kim Barbara; Pink, Daniel; Lindig, Udo; Folprecht, Gunnar; Schuch, Gunter; Bitzer, Michael; Heinemann, Volker; Angermeier, Stefan; Bolling, Claus; Loose, Maria; Junge, Sabine; Pauligk, Claudia; Al-Batran, Salah-Eddin
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial

一线改良FOLFOX方案联合/不联合纳武利尤单抗和伊匹木单抗或FLOT方案联合纳武利尤单抗治疗晚期胃食管腺癌：一项II期多队列试验

期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-026-69622-7
Lorenzen, Sylvie; Goetze, Thorsten Oliver; Thuss-Patience, Peter C; Riera-Knorrenschild, Jorge; Goekkurt, Eray; Dechow, Tobias Nicolaas; Ettrich, Thomas Jens; Hofheinz, Ralf Dieter; Luley, Kim Barbara; Pink, Daniel; Lindig, Udo; Folprecht, Gunnar; Schuch, Gunter; Bitzer, Michael; Heinemann, Volker; Angermeier, Stefan; Bolling, Claus; Loose, Maria; Junge, Sabine; Pauligk, Claudia; Al-Batran, Salah-Eddin
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial

围手术期应用帕博利珠单抗、曲妥珠单抗和FLOT方案治疗HER2阳性局限性食管胃腺癌：一项II期试验

期刊:Nature Medicine
影响因子:50
doi:10.1038/s41591-025-03979-y
Stein, Alexander; Goekkurt, Eray; Al-Batran, Salah-Eddin; Moosmann, Nicolas; Ettrich, Thomas J; Goetze, Thorsten; Gruen, Barbara; Homann, Nils; Lorenzen, Sylvie; Hofheinz, Ralf-Dieter; Rempel, Viktor; Siegler, Gabriele; Müller, Christian; Thiele, Benjamin; Broering, Tobias; Cruz, Mariana Santos; Pauligk, Claudia; Binder, Mascha; Tintelnot, Joseph
肿瘤
肿瘤免疫
HER2
发表日期：2025
文献求助 收藏

Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial

帕尼单抗联合 5-氟尿嘧啶和亚叶酸钙或单独使用 5-氟尿嘧啶和亚叶酸钙作为 RAS 野生型转移性结直肠癌的维持治疗（PanaMa，AIO KRK 0212）：一项随机、开放标签、II 期试验的最终疗效分析

期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2024.103004
Stahler, Arndt; Karthaus, Meinolf; Fruehauf, Stefan; Graeven, Ullrich; Müller, Lothar; Fischer von Weikersthal, Ludwig; Caca, Karel; Goekkurt, Eray; Ballhausen, Alexej; Sommerhäuser, Greta; Alig, Annabel H S; Held, Swantje; Jarosch, Armin; Horst, David; Reinacher-Schick, Anke; Kasper, Stefan; Heinemann, Volker; Stintzing, Sebastian; Trarbach, Tanja; Modest, Dominik P
RAS
肿瘤
肠癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy

炎症应激决定接受靶向治疗和免疫治疗的HER2阳性食管胃腺癌患者是否需要化疗

期刊:Cancer Immunology Research
影响因子:8.2
doi:10.1158/2326-6066.CIR-24-0561
Tintelnot, Joseph; Paschold, Lisa; Goekkurt, Eray; Schultheiss, Christoph; Matschl, Urte; Santos Cruz, Mariana; Bauer, Marcus; Wickenhauser, Claudia; Thuss-Patience, Peter; Lorenzen, Sylvie; Ettrich, Thomas J; Riera-Knorrenschild, Jorge; Jacobasch, Lutz; Kretzschmar, Albrecht; Kubicka, Stefan; Al-Batran, Salah-Eddin; Reinacher-Schick, Anke; Pink, Daniel; Bokemeyer, Carsten; Sinn, Marianne; Lindig, Udo; Hinke, Axel; Hegewisch-Becker, Susanna; Stein, Alexander; Binder, Mascha
肿瘤
炎症
肿瘤免疫
HER2
炎症/感染
免疫/内分泌
发表日期：2025
文献求助 收藏

Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma: The Phase 2 RAP (AIO-STO-0218) Nonrandomized Controlled Trial

雷莫芦单抗、阿维鲁单抗和紫杉醇作为食管胃腺癌二线治疗：RAP (AIO-STO-0218) II期非随机对照试验

期刊:Jama Network Open
影响因子:9.7
doi:10.1001/jamanetworkopen.2023.52830
Thuss-Patience, Peter; Högner, Anica; Goekkurt, Eray; Stahl, Michael; Kretzschmar, Albrecht; Götze, Thorsten; Stocker, Gertraud; Reichardt, Peter; Kullmann, Frank; Pink, Daniel; Bartels, Prisca; Jarosch, Armin; Hinke, Axel; Schultheiß, Christoph; Paschold, Lisa; Stein, Alexander; Binder, Mascha
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552]

对“CA 19-9 在接受多药诱导化疗的局部晚期胰腺癌中的预后和预测价值：一项前瞻性、多中心 II 期试验 (NEOLAP-AIO-PAK-0113) 的结果”的更正：[ESMO Open 7 (2024) 100552]

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103463
Hartlapp, I; Valta-Seufzer, D; Siveke, J T; Algül, H; Goekkurt, E; Siegler, G; Martens, U M; Waldschmidt, D; Pelzer, U; Fuchs, M; Kullmann, F; Boeck, S; Ettrich, T J; Held, S; Keller, R; Anger, F; Germer, C T; Stang, A; Kimmel, B; Heinemann, V; Kunzmann, V
SMO
胰腺癌
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial

在接受 FOLFOX + Pmab 诱导治疗后，RAS 野生型转移性结直肠癌患者接受氟尿嘧啶和亚叶酸钙联合或不联合帕尼单抗 (Pmab) 维持治疗后，皮肤病相关生活质量结局：PanaMa (AIO KRK 0212) II 期随机试验的预设次要分析

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103628
Ballhausen, A; Karthaus, M; Fruehauf, S; Graeven, U; Müller, L; König, A O; von Weikersthal, L F; Sommerhäuser, G; Jelas, I; Alig, A H S; Kurreck, A; Stahler, A; Goekkurt, E; Held, S; Kasper, S; Heinrich, K; Heinemann, V; Stintzing, S; Trarbach, T; Modest, D P
RAS
肿瘤
肠癌
肿瘤免疫
发表日期：2024
文献求助 收藏

Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552]

对“CA 19-9 在局部晚期胰腺癌多药诱导化疗中的预后和预测价值：一项前瞻性、多中心 II 期试验 (NEOLAP-AIO-PAK-0113) 的结果”的更正：[ESMO Open 7 (2024) 100552]

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103705
Hartlapp, I; Valta-Seufzer, D; Siveke, J T; Algül, H; Goekkurt, E; Siegler, G; Martens, U M; Waldschmidt, D; Pelzer, U; Fuchs, M; Kullmann, F; Boeck, S; Ettrich, T J; Held, S; Keller, R; Anger, F; Germer, C T; Stang, A; Kimmel, B; Heinemann, V; Kunzmann, V
SMO
胰腺癌
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial

FOLFOX/贝伐珠单抗+/-伊立替康一线治疗转移性结直肠癌的疗效和生活质量——AIO CHARTA试验的最终结果

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/s41416-023-02496-4
Schmoll, Hans-Joachim; Mann, Julia; Meinert, Fabian; Garlipp, Benjamin; Borchert, Kersten; Vogel, Arndt; Goekkurt, Eray; Kaiser, Ulrich; Hoeffkes, Heinz-Gert; Rüssel, Jörn; Kanzler, Stephan; Edelmann, Thomas; Forstbauer, Helmut; Göhler, Thomas; Hannig, Carla; Hildebrandt, Bert; Roll, Carsten; Bokemeyer, Carsten; Steighardt, Jörg; Cygon, Franziska; Ibach, Stefan; Stein, Alexander; Tintelnot, Joseph
肿瘤
肠癌
肿瘤免疫
发表日期：2024
文献求助 收藏